A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells and placebo in Ocular Corneal Burn, sponsored by Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-08-02.
Sponsored by Guangzhou Saliai Stem Cell Science and Technology Co. Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Burns with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Burns · China.
Among the 24 studies in Burns with a site in China, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 1/2, and was the 6th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →10 of the 24 studies in Burns with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18–65
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18–65
Shanghai Bao Pharmaceuticals Co., Ltd. · Sites in China
Ages 18–65
Queen Mary Hospital, Hong Kong · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 12–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 67 across the 20 interventional studies, 66 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Guangzhou Saliai Stem Cell Science and Technology Co. Ltd. as lead sponsor.
Guangzhou Saliai Stem Cell Science and Technology Co. Ltd. has 1 study filed under Burns — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Burns with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ocular chemical burn is one of the causes of vision loss in China, and there are no satisfactory treatment. Human umbilical cord mesenchymal stem cells(UC-MSCs) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rabbits, the UC-MSCs can accelerated the cornea repair, inhibited angiogenesis. The aim of this study is to access the efficacy and safety of UC-MSCs in the treatment of corneal burn in human.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: human umbilical cord mesenchymal stem cells
Biological: placebo
human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
Saline injection
the percent of cornea perforation
Time frame: 3 months
Start is estimated for Jan 2018; primary completion for Dec 2018, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel